257 related articles for article (PubMed ID: 26617743)
1. Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.
Yu Y; Yu J; Pei CG; Li YY; Tu P; Gao GP; Shao Y
Int J Clin Exp Pathol; 2015; 8(9):10355-64. PubMed ID: 26617743
[TBL] [Abstract][Full Text] [Related]
2. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
Yu Y; Cai W; Pei CG; Shao Y
Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
4. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
5. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
[TBL] [Abstract][Full Text] [Related]
6. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
[TBL] [Abstract][Full Text] [Related]
7. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
8. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
9. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
10. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1α/VEGFR2 signalling axis.
Dewangan J; Kaushik S; Rath SK; Balapure AK
Life Sci; 2018 Jan; 193():9-19. PubMed ID: 29196053
[TBL] [Abstract][Full Text] [Related]
11. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
12. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
13. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
[TBL] [Abstract][Full Text] [Related]
14. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Pang X; Yi Z; Zhang X; Sung B; Qu W; Lian X; Aggarwal BB; Liu M
Cancer Res; 2009 Jul; 69(14):5893-900. PubMed ID: 19567671
[TBL] [Abstract][Full Text] [Related]
16. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
17. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
18. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
[TBL] [Abstract][Full Text] [Related]
19. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
Lin SW; Huang SC; Kuo HM; Chen CH; Ma YL; Chu TH; Bee YS; Wang EM; Wu CY; Sung PJ; Wen ZH; Wu DC; Sheu JH; Tai MH
Mar Drugs; 2015 Feb; 13(2):861-78. PubMed ID: 25668036
[TBL] [Abstract][Full Text] [Related]
20. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
